Oncology Medical News about Rituximab;immunotherapy;Mituprotimut-T;follicular lymphoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma
Journal of Clinical Oncology, 06/22/09

Freedman A et al. - Study demonstrates that time to progression (TTP) was shorter with mitumprotimut-T/GM-CSF compared with placebo/GM-CSF in patients with CD20+ follicular lymphoma. This difference was possibly due to the imbalance in Follicular Lymphoma International Prognostic Index (FLIPI) scores.

Methods

Aim was to evaluate patient-specific immunotherapy with mitumprotimut-T and GM-CSF in CD20+ follicular lymphoma
Patients: treatment-naive or relapsed/refractory disease achieving a CR, PR, or SD with 4 weekly rituximab infusions
Pts randomly assigned to mitumprotimut-T/GM-CSF or placebo/GM-CSF
Doses: monthly for 6 doses, every 2 mo for 6 doses, and then every 3 mo until disease progression (PD)
Randomization was stratified by prior therapy and response to rituximab
Primary end point: TTP from randomization

Results

349 pts; median age: 54 yrs; 79% were treatment naive, and 86% had stage III/IV disease
Median TTP was 9.0 mo for mitumprotimut-T/GM-CSF and 12.6 mo for placebo/GM-CSF
TTP was comparable between the 2 arms in treatment-naive pts and shorter with mitumprotimut-T/GM-CSF in relapsed/refractory disease
After adjusting for FLIPI scores, the difference in TTP between the 2 arms was no longer significant
Overall objective response rate, rate of response improvement, and duration of response were comparable between the 2 arms
Toxicity was similar in the 2 arms:
- 76% of adverse events were mild or moderate, and
- 94% of patients had injection site reactions

<< Previous
Phase III postoperative adjuvant radiotherapy after radical...

Next >>
Efficacy, safety, and potential biomarkers of sunitinib...

Treatment of adult inflammatory myositis with rituximab: An emerging therapy for refractory patients
Journal of Clinical Rheumatology (JCR), 10/08/09 Relevance Score: 90%

Prognostic models for diffuse large B-cell lymphoma in the rituximab era: A never-ending story
Annals of Oncology, 11/24/09 Relevance Score: 89%

Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection
Nephrology, 10/07/09 Relevance Score: 89%

Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: Effects of rituximab
Annals of Oncology, 11/10/09 Relevance Score: 88%

Prevention of hepatitis B virus reactivation under rituximab therapy
Immunotherapy, 11/06/09 Relevance Score: 88%